Stiefel completes acquisition

Skin & Allergy News, Sept, 2008 by Alicia Ault

Stiefel Laboratories has completed its purchase of Barrier Therapeutics, a Princeton, N.J.-based company that has three topical products on the market, Xolegel, Vusion, and Solage. "Barrier's innovative products and pipeline are a very valuable addition to Stiefel," company CEO Charles W. Stiefel said in a statement.

With the purchase of Barrier, Stiefel adds a development portfolio that includes products for onychomycosis, psoriasis, acne, skin allergies, and acute fungal infections. The family-owned Stiefel claims to be the world's largest dermatologic specialty pharmaceutical company. It does not publicly report sales or earnings.